GSC
IONS icon

Ground Swell Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Ground Swell Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,285
Closed -$547K – 179
2026
Q1 		$547K Buy
+7,285
New +$575K 1.08% 19
2014
Q3 		– Sell
-1,774
Closed -$61K – 2575
2014
Q2 		$61K Buy
+1,774
New +$55.9K 0.12% 110

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Ground Swell Capital's IONS Position: Q2 2026 in Review

Ground Swell Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 7,285 shares — an estimated $547K sold.

Ground Swell Capital first reported a position in IONS in Q2 2014 and held it in 2 quarters. The position peaked at $547K in Q1 2026. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Ground Swell Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ground Swell Capital sold 7,285 Ionis Pharmaceuticals shares in Q2 2026, an estimated $547K.
  • Ground Swell Capital first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Ground Swell Capital's Ionis Pharmaceuticals position peaked at $547K in Q1 2026.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Ground Swell Capital's 13F filing for Q2 2026, filed 5 Aug 2026.